Developer · PFE · United States

Pfizer Inc.

pfizer.com ↗

1compound
1program
1indication
Phase 2lead asset

Phase distribution

  • Phase 21

Modality

  • Small molecule 1

Mechanism focus

Pipeline (1)

Deals & partnerships

Catalysts · 0 upcoming · 2 reported

Recently reported

  • 2025-10-15

    PF-06412562 (CVL-562)forSchizophreniaRegistry results

    Results of the Yale-led TRANSCENDS Phase 2 target-engagement study of CVL-562 in early-course schizophrenia posted to ClinicalTrials.gov.

    source ↗

  • 2019-07-02missed

    PF-06412562 (CVL-562)forSchizophreniaFull results

    Phase 1b of PF-06412562 in stable schizophrenia: safe and well tolerated, but no benefit over placebo on working memory, reward processing or 2-back accuracy over 15 days.

    source ↗

Recent activity

  • Oct 15, 2025ReadoutPF-06412562 (CVL-562)·SchizophreniaResults of the Yale-led TRANSCENDS Phase 2 target-engagement study of CVL-562 in early-course schizophrenia posted to ClinicalTrials.gov.source ↗
  • Mar 2, 2021Phase changePF-06412562 (CVL-562)·SchizophreniaPhase 2Yale-led, NIMH-funded Phase 2 target-engagement study TRANSCENDS (NCT04457310) of CVL-562 in early-course schizophrenia started; Cerevel Therapeutics is a collaborator.source ↗
  • Jul 2, 2019ReadoutPF-06412562 (CVL-562)·SchizophreniamissedPhase 1b of PF-06412562 in stable schizophrenia: safe and well tolerated, but no benefit over placebo on working memory, reward processing or 2-back accuracy over 15 days.source ↗
  • Oct 1, 2016Phase changePF-06412562 (CVL-562)·SchizophreniaPhase 1NCT02418819 completed October 2016 (month precision); published results showed no benefit over placebo on cognition or reward processing.source ↗
  • Apr 1, 2015Phase changePF-06412562 (CVL-562)·SchizophreniaPhase 1Pfizer Phase 1b study B7441007 (NCT02418819) in psychiatrically stable patients with schizophrenia started April 2015 (month precision on the registry).source ↗

Trials recruiting · 8 recruiting of 218 sponsored

  • Phase 4Rimegepantn=4003 sites · United States

    A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine

    Acute Treatment of MigraineNCT07609914 ↗

  • Phase 3Rimegepant, Placebo Comparator, Standard of Caren=723123 sites · United States, China, Spain

    A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

    Menstrual MigraineNCT06641466 ↗

  • Phase 3Rimegepant, Placebon=200103 sites · United States, China, Poland

    A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

    MigraineNCT06616194 ↗

  • Phase 3Rimegepant, Placebon=64091 sites · United States, Japan, Poland

    Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

    MigraineNCT05156398 ↗

  • Phase 3Rimegepant (PF-07899801)n=600126 sites · United States, Poland, Spain

    Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

    Acute Treatment of MigraineNCT04743141 ↗

  • Phase 3Rimegepant/BHV3000, Matching placebon=2100246 sites · United States, China, Japan

    Randomized Study in Children and Adolescents With Migraine: Acute Treatment

    Pediatric MigraineNCT04649242 ↗

  • Phase 1ODT2 Test formulation, ODT Reference formulationn=361 site · Belgium

    A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults

    MigraineNCT07594769 ↗

  • Phase 1Zavegepantn=1613 sites · United States

    A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine

    Acute Treatment of MigraineNCT06995729 ↗

Competitive landscape

Other companies developing against Pfizer Inc.'s targets or indications.